David Watson - 21 Apr 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
General Counsel
Signature
/s/ David Watson
Issuer symbol
APLS
Transactions as of
21 Apr 2022
Transactions value $
-$250,000
Form type
4
Filing time
27 Apr 2022, 16:39:52 UTC
Previous filing
14 Feb 2022
Next filing
23 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Other $0 -1.88K -1.42% $0.00 131K 21 Apr 2022 Direct F1
transaction APLS Common Stock Sale -$250K -5K -3.83% $50.00 126K 25 Apr 2022 Direct F2
holding APLS Common Stock 3.33K 21 Apr 2022 Indirect Owner (Custodial Account for Son) F3
holding APLS Common Stock 6.67K 21 Apr 2022 Indirect Owner (The Watson Education Trust) F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Other $0 -11.3K -100% $0.00* 0 21 Apr 2022 Common Stock 11.3K $44.90 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
F2 This is a scheduled sale from an established 10B5-1 trading plan.
F3 This represents a custodial account held by the reporting person for the sole benefit of his minor son.
F4 The securities are held by The Watson Education Trust (the "Trust"), for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.
F5 This represents the cancellation of a performance stock option granted on 01/28/01. The performance metrics were not met.
F6 This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.